Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.38 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.37 |
| ▸ | CTPS1 | P17812 | 4/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.34 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.34 |
| ▸ | CKS1B | P61024 | 1/20 | 0.33 |
| ▸ | SKP2 | Q13309 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30623300 | 1.00 | KDM4E (0.43) | KDM4EABL1MAP4K1CTPS1ALDH1A1 | |
| SCHEMBL30623231 | 0.85 | KDM4E (0.40) | KDM4EABL1MAP4K1CTPS1ALDH1A1 | |
| SCHEMBL3123445 | 0.85 | KDM4E (0.40) | KDM4EABL1MAP4K1CTPS1ALDH1A1 | |
| SCHEMBL25359599 | 0.85 | KDM4E (0.40) | KDM4EABL1MAP4K1CTPS1ALDH1A1 | |
| SCHEMBL30623323 | 0.77 | ABL1 (0.39) | KDM4EABL1MAP4K1CTPS1ALDH1A1 | |
| SCHEMBL25355967 | 0.77 | ABL1 (0.39) | KDM4EABL1MAP4K1CTPS1ALDH1A1 | |
| SCHEMBL3123439 | 0.72 | NNMT (0.54) | — | |
| SCHEMBL14830949 | 0.69 | TSHR (0.53) | KDM4EALDH1A1PTGS1PTGS2TDP1 | |
| SCHEMBL30339075 | 0.69 | TSHR (0.53) | KDM4EALDH1A1PTGS1PTGS2TDP1 | |
| SCHEMBL22581904 | 0.68 | HTR2A (0.50) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250171459-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMA (US) | 2025-05-29 | — | — | US | disclosed |
| EP-4476227-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | Vertex Pharmaceuticals Incorporated (US) | 2024-12-18 | — | — | EP | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
| WO-2023154344-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2023-08-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250171459-A1 | 2-METHYL-4',5'-DIHYDROSPIRO[PIPERIDINE-4,7'-THIENO[2,3-C]PYRAN] DERIVATIVES AS INHIBITORS OF APOL1 AND METHODS OF USING SAME | APOL1, PDXK, PNLIP | KDM4E 3628/4885ABL1 2689/4885MAP4K1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.